Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy

Author： Charland Scott L. Malone Daniel C.

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.2, 2010-02, pp. : 365-375

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evolving Role of Non‐Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 164-171

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction

By Brown Siobhan HM Abdelhafiz Ahmed H

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 515-529

Future Medicine

Access to resources Recommend Favorite

New Fixed‐Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High‐Risk Patients with Mixed Dyslipidemia Versus Monotherapies

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 33, Iss. 6, 2015-12 ,pp. : 329-337

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alternate approaches to managing lipid-associated cardiovascular risk

By Hsia Stanley H

Future Lipidology, Vol. 2, Iss. 2, 2007-04 ,pp. : 157-163

Future Medicine

Access to resources Recommend Favorite

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care

By Bestehorn Kurt Smolka Wenefrieda Pittrow David Schulte Helmut Assmann Gerd

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2833-2839

Informa Healthcare

Access to resources Recommend Favorite